Ph.D, AFHEA
Senior Equality, Diversity and Inclusion Partner
- About
-
- Email Address
- m.cascio@abdn.ac.uk
- Office Address
- School/Department
- Directorate of People
Biography
I graduated in July 2002 in Chemistry and Pharmaceutical Technologies (Master degree-UK equivalent) from the University of Palermo (Italy), obtaining the highest mark possible under the system (110/110 cum laude).
From September 2000 to June 2007 I was based in Naples where I joined the “Endocannabinoid Research Group”, at the National Council of Research. There, I started my research aimed at understanding the involvement of the “Endocannabinoid System” in both pathological and physiological conditions.
In 2006 I obtained my PhD in Pharmaceutical Chemistry (University of Fisciano, Salerno, Italy).
In 2007, I moved to the University of Aberdeen and as Research Fellow (supported by GW Pharmaceuticals) I have been involved, in collaboration with Professor Roger Pertwee, in the pharmacological in vitro characterization of new Cannabis-derived cannabinoids. In 2014 I was promoted to Research Fellow, Grade 7 (Lecturer grade).
I am co-author of more than 80 peer-reviewed papers and 6 book chapters. You can see my publications here:
http://www.ncbi.nlm.nih.gov/pubmed/?term=Cascio+MG
Currently, I am University Senior Equality, Diversity and Inclusion Partner supporting work aimed at addressing the barriers faced by underrepresented groups. If you wish to get in touch, please email me! m.cascio@abdn.ac.uk
Qualifications
- PhD Pharmaceutical Chemistry2006 - University of Fisciano, Salerno, Italy
Memberships and Affiliations
- Internal Memberships
-
Membership of Professional Bodies/Committees/Worki
Clerk and active member of the University Race Equality Strategy Group
Member of the University Equality, Diversity and Inclusion Committee
Member of School Equality, Diversity and Inclusion Committees (STEMM)
Member of the University Annual Review Steering Group
Social Bias Observer at Promotions Committees
- External Memberships
-
Professional activities
- Radiation Protection Supervisor, Level 6th, Institute of Medical Sciences, University of Aberdeen, (2012-2014).
- Guest Associate Editor, Frontiers in Neuropharmacology, Research topic:”Additive drugs targeting GPCRs: new cross-talk mechanisms" (2013-2014).
- Associate Fellow of the Higher Education Academy, since 2012
- Paper co-evaluator at F1000 faculty (www.F1000biology.com)
- Peer reviewer of international scientific journals
- Book reviewer: “Cannabinoids in Nature and Medicine”, Didier M. Lambert Editor
- Research
-
Research Overview
Main research interests are:
. Medicinal chemistry
. Pharmacology and therapeutic potential of plant cannabinoids
· Pharmacology of allosteric sites on cannabinoid receptors
· Novel cannabinoid CB1 and CB2 receptor ligands
· New pharmacological targets for cannabinoids
· Roles of the endocannabinoid system in health and disease
. Anti-proliferative effects of the omega 3 fatty acids/ethanolamides in prostate cancer
Technical Experience
Biochemistry assays: Western Blotting, PCR, Plasmid Transfection, Lipid extraction from tissues and cells.
Immunofluorimetric assays: p-ERK 1/2 AlphaScreen®, SureFire® (Envision, Perkin Elmer), E.L.I.S.A., cyclic AMP, β-arrestin.
Pharmacological assay: [35S]GTPγS binding, [3H]Displacement binding, Impedance-based system (RT-CES®) for dynamic monitoring of GPCRs activation in living cells.
Chromatography (Silica gel and HPLC).
Cells culturing
Simple synthesis of chemical tools
Current Research
Maria Grazia Cascio's current research is directed at elucidating the pharmacological actions of plant cannabinoids such as cannabidiol (CBD), delta-9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG). In addition, she is currently involved in projects aimed at identifying new potent and selective ligands for the cannabinoid CB1 and CB2 receptors. For this she is collaborating with chemists based in Italy.
My research also focuses on the study of the anti-proliferative effects of two fish oil omega 3 fatty acids (DHA and EPA) and their ethanolamides (DHEA and EPEA) in two prostate cancer cell lines, PC3 and LNCaP.
Collaborations
Internal collaborators
Dr Iain Brown (Project: Prostate cancer)
Professor Matteo Zanda (Project: New CB1 ligands for PET)
Dr Mirela Delibegovic (Project: The study of the involvement of the endocannabinoid system in diabetic nephropathy).
External collaborators
Dr Ben Whalley, University of Reading (Project: The anticonvulsant properties of some plant-derived cannabinoids);
Professor Angelo Izzo, University “Federico II” of Naples (Project: The ability of some plant-derived cannabinoids to ameliorate murine colitis;
Professor Daniela Parolaro, University of Milan (Project: The ability of some plant-derived cannabinoids to ameliorate schizophrenia);
Dr Barbara Costa, University of Busto Arstizio (Project: Investigation of the analgesic properties of the plant-derived cannabigerol),
Dr Ganesh Takhur, (Department of Pharmaceutical Sciences, Northeastern University, Boston) (Project: Investigation of the pharmacological profile of new synthetic CB1 cannabinoid receptor Positive Allosteric Modulators);
Professor Federico Corelli and Dr Antonella Brizzi, (University of Siena),
Professor Giovanni Appendino (University of Novara);
Professor Romano Silvestri and Professor Giorgio Ortar (University of Rome).
Funding and Grants
Delibegovic M, Cascio MG and Pertwee RG. Diabetes. Eighteen months (2014-2016).
Takhur G, Cascio MG, Pertwee RG et al.,. NIDA. Five years (2014 to 2019).
Pertwee RG and Cascio MG. Honours Student Project, 10 weeks (January 2014 - March 2014), University of Aberdeen,
Cascio MG. Summer student from Brazil, 3 months (June 2013 - August, 2013), University of Aberdeen,
Cascio MG, Marini P, Brown I, Pertwee R.G. NHS Grampian Endowment Research Fund, Scotland, UK. One year (April 2013- March 2014). .
Brown I, Cascio MG, Sneddon AA, Wahle KWJ, Pertwee RG, Heys SD. Fraserburgh Moonlight Prowl and University of Aberdeen. PhD studentship in Nutrition and Cancer. Three years (2010 to 2013). Student stipend, home/EU fees and consumables.
Cascio MG and Pertwee RG. Honours Student Project, 10 weeks (January 2012 - March 2012), University of Aberdeen,
Brown I, Cascio MG, Heys SD, Pertwee RG. & Ross RA. Tenovus Scotland. One year (April 2010-March 2011).
Brown I, Cascio MG. & Pertwee RG. NHS GRAMPIAN ENDOWMENTS. One year (April 2010-March 2011).
- Teaching
-
Teaching Responsibilities
Supervisor of both undergraduate and PhD students
Student tutor in Life Sciences subjects
- Publications
-
Page 5 of 8 Results 41 to 50 of 79
Investigations on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2 receptor ligands.
Journal of Medicinal Chemistry, vol. 53, no. 16, pp. 5915-5928Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1021/jm100123x
The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice
British Journal of Pharmacology, vol. 160, no. 3, pp. 677-687Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1111/j.1476-5381.2010.00756.x
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists
Pharmacological Research, vol. 61, no. 4, pp. 349-354Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.phrs.2009.11.011
A gradient of 2-arachidonoylglycerol regulates mouse epididymal sperm cell start-up.
BIOLOGY OF REPRODUCTION, vol. 82, no. 2, pp. 451-458Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1095/biolreprod.109.079210
- [ONLINE] View publication in Scopus
Evidence that the plant cannabinoid cannabigerol is a highly potent α2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist
British Journal of Pharmacology, vol. 159, no. 1, pp. 129-141Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1111/j.1476-5381.2009.00515.x
Rational design, synthesis, and pharmacological properties of new 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists
Journal of Medicinal Chemistry, vol. 52, no. 12, pp. 3644-3651Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1021/jm801563d
- [ONLINE] View publication in Scopus
Conformationally Constrained Fatty Acid Ethanolamides as Cannabinoid and Vanilloid Receptor Probes
Journal of Medicinal Chemistry, vol. 52, no. 9, pp. 3001-3009Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1021/jm900130m
New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo
Journal of Medicinal Chemistry, vol. 52, no. 8, pp. 2506-2514Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1021/jm8016255
- [ONLINE] View publication in Scopus
The endocannabinoid system: A general view and latest additions
Contributions to Journals: Short Survey- [ONLINE] DOI: https://doi.org/10.1038/sj.bjp.0705666
- [ONLINE] View publication in Scopus
New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis
British Journal of Pharmacology, vol. 147, no. 1, pp. 83-91Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/sj.bjp.0706418
- [ONLINE] View publication in Scopus